GH Research PLC (NASDAQ:GHRS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS) have been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $40.1250.

Several research firms recently weighed in on GHRS. TD Cowen reaffirmed a “buy” rating on shares of GH Research in a research note on Monday, January 5th. Needham & Company LLC increased their price objective on shares of GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a report on Friday, March 6th. Canaccord Genuity Group raised their price objective on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada lifted their target price on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Finally, Wolfe Research set a $39.00 target price on GH Research in a research report on Tuesday, January 6th.

Institutional Trading of GH Research

Several hedge funds have recently modified their holdings of GHRS. Barclays PLC boosted its position in shares of GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares during the last quarter. Osaic Holdings Inc. increased its position in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the last quarter. Jefferies Financial Group Inc. raised its stake in GH Research by 0.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in GH Research during the fourth quarter valued at $38,000. Finally, JPMorgan Chase & Co. bought a new position in GH Research during the second quarter valued at $79,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Price Performance

GHRS stock opened at $15.11 on Tuesday. GH Research has a 1-year low of $7.98 and a 1-year high of $19.51. The business has a 50 day simple moving average of $15.71 and a two-hundred day simple moving average of $14.35. The company has a market capitalization of $937.27 million, a price-to-earnings ratio of -18.89 and a beta of 1.00.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.06. Sell-side analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.